Photocure ASA's latest marketcap:
As of 06/18/2025, Photocure ASA's market capitalization has reached $134.64 M. According to our data, Photocure ASA is the 22485th most valuable company globally by market capitalization. Market capitalization, commonly referred to as market cap, represents the total market value of all outstanding shares of a publicly traded company and is often used as a measure of company value.
| Market Cap | 134.64 M |
| Revenue (ttm) | 53.59 M |
| Net Income (ttm) | 215,089.21 |
| Shares Out | 26.61 M |
| EPS (ttm) | 0.01 |
| Forward PE | 140.88 |
| Ex-Dividend Date | n/a |
| Earnings Date | 07/30/2025 |
Photocure ASA's yearly market capitalization.
| Date | Market Cap | Change (%) | Global Rank |
|---|---|---|---|
| 06/18/2025 | kr134.64 M | -19.1% | 22485 |
| 12/30/2024 | kr1.68 B | -8.01% | 20843 |
| 12/29/2023 | kr1.83 B | -36.89% | 19477 |
| 12/30/2022 | kr2.89 B | 4.55% | 15660 |
| 12/30/2021 | kr2.77 B | -2.73% | 16198 |
| 12/30/2020 | kr2.85 B | 46.02% | 13960 |
| 12/30/2019 | kr1.95 B | 86.59% | 14287 |
| 12/28/2018 | kr1.04 B | 77.51% | 16312 |
| 12/29/2017 | kr588.51 M | -35% | 19735 |
| 12/30/2016 | kr905.4 M | 0.78% | 15746 |
Company Profile
About Photocure ASA
Photocure ASA, along with its subsidiaries, specializes in the research, development, production, and commercialization of pharmaceutical products. The company operates across multiple regions, including:
- Nordic countries
- Germany, France, Austria
- United Kingdom and BeNeLux
- Italy and other European countries
- Canada and the United States
Business Segments
The company operates through two primary segments:
- Commercial Franchise: Focuses on established pharmaceutical products.
- Development Portfolio: Concentrates on innovative treatments in development.
Key Products
- Hexvix/Cysview: Used for the detection and management of bladder cancer.
- Cevira (in development): A treatment for HPV-induced cervical precancerous lesions.
Strategic Partnerships
Photocure ASA has established key collaborations to enhance its product offerings:
- Asieris MediTech Co: License agreement for the development and commercialization of Cevira.
- Richard Wolf GmbH: Strategic partnership to develop a next-generation 4K LED HD reusable flexible blue light cystoscope.
Distribution Network
The company sells its products through:
- Pharmaceutical wholesalers
- Pharmacies
- Hospitals via license partners
Founded: 1993 | Headquarters: Oslo, Norway
Frequently Asked Questions
-
What is Photocure ASA's (OSL-PHO) current market cap?As of 06/18/2025, Photocure ASA (including the parent company, if applicable) has an estimated market capitalization of $134.64 M USD. This figure represents the total market value of its outstanding shares, including different share classes. Please note that market capitalization fluctuates based on market conditions, and the actual valuation may differ from the latest estimate.
-
Where does Photocure ASA (OSL-PHO) rank globally by market cap?Photocure ASA global market capitalization ranking is approximately 22485 as of 06/18/2025. This ranking is relative to all publicly traded companies worldwide and can fluctuate based on market dynamics and the performance of other companies. You can refer to our Global companies market cap ranking for the most up-to-date ranking.